首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody.
【2h】

Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody.

机译:人血浆激肽释放酶和C1抑制剂形成一种复合物该复合物具有在亲本分子上无法检测到的表位:使用单克隆抗体的演示。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The inactivation of human plasma kallikrein (EC 3.4.21.8) by the inhibitor of activated complement component 1 (C1 inhibitor) induces the formation of a 1:1 stoichiometric kallikrein-C1 inhibitor complex and a proteolytically modified form of C1 inhibitor. We have produced a monoclonal antibody that recognizes the kallikrein-C1 inhibitor complex as well as modified C1 inhibitor but fails to react with virgin C1 inhibitor or native plasma kallikrein. This observation constitutes an unequivocal demonstration that the reaction between plasma kallikrein and C1 inhibitor leads to the emergence of an epitope that is undetectable on the parent enzyme and inhibitor molecules.
机译:活化补体成分1的抑制剂(C1抑制剂)使人血浆激肽释放酶(EC 3.4.21.8)失活,诱导形成化学计量的1:1激肽释放酶-C1抑制剂复合物和蛋白水解修饰形式的C1抑制剂。我们生产了一种单克隆抗体,可以识别激肽释放酶-C1抑制剂复合物以及修饰的C1抑制剂,但无法与原始C1抑制剂或天然血浆激肽释放酶反应。该观察结果明确表明血浆激肽释放酶和C1抑制剂之间的反应导致表位的出现,该表位在亲本酶和抑制剂分子上无法检测到。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号